Antitumor Activity of Larotrectinib in Tumors Harboring NTRK Gene Fusions: A Short Review on the Current Evidence [Corrigendum]
Ricciuti B, Genova C, Crinò L, Libra M, Leonardi GC. Onco Targets Ther. 2019;12:3171–3179. Lucio Crinò has advised that affiliation 3 is incorrect. The correct affiliation 3 should be as follows:Department of Medical Oncology, Istituto Scientifico&am...
Main Authors: | Ricciuti B, Genova C, Crinò L, Libra M, Leonardi GC |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2020-05-01
|
Series: | OncoTargets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/corrigendum-antitumor-activity-of-larotrectinib-in-tumors-harboring-nt-peer-reviewed-article-OTT |
Similar Items
-
Antitumor activity of larotrectinib in tumors harboring NTRK gene fusions: a short review on the current evidence
by: Ricciuti B, et al.
Published: (2019-04-01) -
Larotrectinib in a NTRK‐rearranged soft tissue sarcoma in the neoadjuvant setting: A case report
by: Catherine Percy, et al.
Published: (2021-03-01) -
NTRK-A narrative review
by: Ullas Batra, et al.
Published: (2021-01-01) -
A novel NCOR2-NTRK1 fusion detected in a patient of lung adenocarcinoma and response to larotrectinib: a case report
by: Lei Zhang, et al.
Published: (2021-04-01) -
Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative Analysis
by: Antoine Italiano, et al.
Published: (2020-11-01)